What guidelines apply to the examination of patent applications containing nucleotide sequences?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice.
The examination of patent applications containing nucleotide sequences is subject to specific guidelines. According to MPEP 2434:
“All pending applications are subject to Examination of Patent Applications Containing Nucleotide Sequences, 1316 OG 123 (March 27, 2007).”
This guideline provides specific instructions for examiners when dealing with applications that include nucleotide sequences. It’s important to note that these guidelines apply to all pending applications, ensuring consistency in the examination process for biotechnology-related inventions.